QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-26

RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target f...

 hc-wainwright--co-maintains-buy-on-nurix-therapeutics-raises-price-target-to-26

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price targ...

 whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

 jp-morgan-maintains-overweight-on-nurix-therapeutics-raises-price-target-to-31

JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...

 needham-reiterates-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

 reported-sunday-nurix-therapeutics-confirms-efficacy-of-nx-5948-in-relapsed-cll-with-692-objective-response-presented-at-eha2024

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resi...

 nurix-therapeutics-inc-files-for-mixed-shelf-size-not-disclosed

-SEC Filing

 piper-sandler-maintains-overweight-on-nurix-therapeutics-maintains-35-price-target

Piper Sandler analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and maintains $35 price ...

 stifel-maintains-buy-on-nurix-therapeutics-maintains-27-price-target

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $27 price target.

 needham-reiterates-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

 nurix-therapeutics-upcoming-oral-presentation-of-data-from-ongoing-clinical-trial-of-nx-5948-a-selective-btk-degrader-at-eha2024-june-13---16-2024-in-madrid-spain

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical response...

 stephens--co-initiates-coverage-on-nurix-therapeutics-with-overweight-rating-announces-price-target-of-20

Stephens & Co. analyst Sudan Loganathan initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Overweight rating ...

 why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.